Form 4: Denali Therapeutics Director Marc Tessier-Lavigne Reports Significant Equity Grant

Denali Therapeutics Inc. Director Marc Tessier-Lavigne has reported the acquisition of 6,037 Restricted Stock Units and 18,111 stock options, aligning his interests with shareholders.

Summary

• Marc Tessier-Lavigne, a Director of Denali Therapeutics Inc. (DNLI), reported an acquisition of equity securities on June 3, 2025.
• He acquired 6,037 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs are contingent rights to receive one share of common stock and will vest upon the earlier of the one-year anniversary of the grant date or the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
• Following this transaction, Mr. Tessier-Lavigne directly beneficially owns 1,886,576 shares of Common Stock, which includes the 6,037 unvested RSUs.
• He also indirectly beneficially owns 78,848 shares through The Tessier-Lavigne/Hynes Irrevocable Trust 1, 79,173 shares through The Tessier-Lavigne/Hynes Irrevocable Trust 2, and 78,848 shares through The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which he serves as trustee.
• Additionally, Mr. Tessier-Lavigne acquired 18,111 Stock Options (right to buy) with an exercise price of $13.93 per share.
• These stock options will vest under the same conditions as the RSUs: upon the earlier of the one-year anniversary of the grant date or the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
• The stock options have an expiration date of June 3, 2035.
• Following this transaction, he directly beneficially owns 18,111 derivative securities in the form of stock options.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates a director receiving equity compensation, which aligns their interests with shareholders. This is a routine filing and not indicative of significant operational news.

Positives

• The grant of Restricted Stock Units (RSUs) and stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The acquisition of equity at a $0 price for RSUs and a defined exercise price for options is a standard component of executive and director compensation packages, reflecting confidence in future value.

Risks

• The value of the unvested RSUs and stock options is subject to the future performance of Denali Therapeutics' common stock price.
• The vesting conditions mean that the director must remain with the company for a certain period or until the next annual meeting to fully realize the value of these grants.

Future Outlook

The vesting schedules for the granted RSUs and stock options indicate a forward-looking compensation structure designed to incentivize the director's continued contribution and alignment with the company's long-term success. The full realization of these equity awards is contingent on future stock performance and the fulfillment of vesting conditions.

Industry Context

The granting of Restricted Stock Units and stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including for companies like Denali Therapeutics. This compensation structure is widely used to attract and retain top talent, align the interests of directors with those of shareholders, and incentivize long-term value creation in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• The compensation structure involving RSUs and stock options for directors is a standard practice across the biotechnology and pharmaceutical industries, comparable to compensation packages observed at companies like Biogen Inc. (BIIB), Amgen Inc. (AMGN), and Gilead Sciences, Inc. (GILD).
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is typical for director equity grants, ensuring continued engagement and oversight.
• The grant of RSUs at a $0 price is standard for such awards, representing a direct equity stake, while the stock option exercise price of $13.93 would typically be set at the fair market value on the grant date, a common industry benchmark.

Corporate Governance

Related Party Transactions

• Marc Tessier-Lavigne indirectly holds shares through The Tessier-Lavigne/Hynes Irrevocable Trust 1 (78,848 shares), The Tessier-Lavigne/Hynes Irrevocable Trust 2 (79,173 shares), and The Tessier-Lavigne/Hynes Irrevocable Trust 3 (78,848 shares), for which he serves as trustee. These are considered related party holdings.

Stakeholder Impact

• Shareholders: The equity grant to a director is intended to align their interests with shareholders, potentially leading to better long-term decision-making and value creation.
• Employees: While not directly impacting general employees, such compensation practices for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• The RSUs and stock options will vest upon the earlier of the one-year anniversary of the grant date (June 3, 2026) or the day preceding Denali Therapeutics' next annual meeting of stockholders occurring after the grant date.

Key Dates

Keywords

Denali Therapeutics, DNLI, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Options, Director Compensation, Beneficial Ownership